Skip to main content

Table 1 Patient characteristics

From: Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study

Characteristics

 

All patients (n = 21)

Gender

Male

10 (48%)

 

Female

11 (52%)

Age

Median (range)

69.6 (55 – 82)

ECOG PS*

0

7 (33%)

 

1

13 (62%)

 

2

1 (5%)

Metastatic site (duplication)

Lymph node

14 (67%)

 

Lung

14 (67%)

 

Bone

6 (29%)

 

Others**

4 (19%)

Histology

Papillary

21 (100%)

Median TSH (range)

 

0.45 μIU/mL (< 0.01 – 15.61)

Median FT3 (range)

 

2.3 pg/dL (1.6 – 11.3)

Median FT4 (range)

 

1.8 ng/mL (0.9 – 3.5)

Thyroglobrin (range)

 

378.2 ng/mL (1.5 – 70,909)

Median SUVmax (range)

 

27.7 (5.3 – 84.8)

Median MTV (range)

 

48.4 (1.4 – 471.4)

Median TLG (range)

 

376.5 (5.7 – 2181.8)

  1. *Eastern cooperative oncology group performance status
  2. **Others included adrenal, pancreas, pleura, and brain